Geoff is our President & CEO and brings over 20 years of industry leadership as CEO of several innovative biotech companies. Previously, he was founding CEO of AVROBIO Inc., developing hematopoietic gene therapy from concept to late-stage trials and ultimately a sale of their lead program to Novartis. Geoff was also the founding CEO of eGenesis Inc., a company dedicated to applying gene editing to xenotransplantation. During his tenure as CEO of Organogenesis Inc., the company received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and treated one million patients with living cell therapies. 

Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions, culminating as Vice-President Transplantation & Immunology. Past and present board activities include Chairman of the Board of Satellos Bioscience, Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts. 

Geoff was recognized as Ernst & Young's "Entrepreneur of the Year” for New England.

Philip serves as our Chief Technology Officer and co-founder of Fable Therapeutics, where his expertise in machine learning methods for protein design has established him as a world-leading expert. For the past 15 years, he has held a professorship at the University of Toronto's Donnelly Centre and in the Departments of Computer Science and Molecular Genetics.

In his academic research, Philip has been at the forefront of the machine learning revolution in protein design. Alongside his lab team, he has pioneered novel methods for protein and peptide engineering, resulting in over 90 publications, 7 invention disclosures, and 5 patent applications.

Philip's contributions extend beyond academia; he has played pivotal roles as a co-founder, consultant, and member of the scientific advisory boards for various biotechnology companies, including TBG Therapeutics, Zymedi, and Synepark Therapeutics. Prior to his academic career, he honed his skills as a postdoctoral fellow at Yale University and as an associate at McKinsey & Co.

He earned his Ph.D. from the Massachusetts Institute of Technology's Artificial Intelligence Laboratory and Department of Chemistry, complemented by a dual Bachelor's degree in Physics and Biochemistry from the University of Tuebingen, Germany.

Dave is Chief Scientific Officer at Fable, bringing over 20 years of drug discovery experience with leading biopharmaceutical companies including AstraZeneca/MedImmune, Merck, and Pfizer. His career has focused on developing innovative therapies for diabetes, obesity, MASH, chronic kidney disease (CKD), and dyslipidaemia—spanning the full spectrum from target discovery to Phase 2b clinical development.

Prior to joining Fable in 2025, Dave spent 16 years at AstraZeneca, holding senior roles across Metabolic Disease R&D. From 2009 to 2019, he served as Team Leader of in vivo pharmacology and later as Principal Scientist and Research Director at MedImmune, with a focus on obesity, diabetes, and CKD. From 2019 to 2025, he was Executive Director and Global Head of Metabolism Bioscience, leading AstraZeneca’s metabolism teams across Sweden, the UK, and the US. Under his leadership, the department advanced 12 drug candidates into clinical development and shaped the global metabolism disease area strategy.

Dave also played a central role in several strategic collaborations, serving on Joint Steering Committees with Ionis Pharmaceuticals, Regeneron, and Cholesgen, and contributing to successful in-licensing efforts with Eccogene and Quell.

He holds a First-Class Honours degree in Physiology and Pharmacology and a PhD in skeletal muscle function and energy metabolism from Nottingham University Medical School. He also completed post-doctoral research at the University of Calgary, Canada, studying the effects of long-term caloric restriction on ageing and sarcopenia.

Rhonda serves as Fable’s Chief Business Officer, with 15 years of experience leading a wide variety of transactions, core R&D collaborations and corporate strategy initiatives across private and public biotechnology companies, from start-up to late clinical stage.

Prior to joining Fable in 2024, Rhonda led corporate development activities for Innovakine Therapeutics, a VC-backed start-up developing a novel approach for in vivo control of therapeutic immune cells. 

She previously worked in progressively senior roles spanning transactions, alliance management, market and competitive intelligence, and corporate strategy functions at Zymeworks Inc., a clinical-stage public biopharmaceutical company focused on multifunctional therapeutics.

Rhonda holds a PhD from University of British Columbia, where her research focused on novel approaches for treating diabetes using cellular and gene therapy, and an MBA in Management of Biotechnology from Simon Fraser University.

Vanita brings over 15 years of experience in drug discovery, at the forefront of drug discovery across small & large molecules.  She has a track record of delivering optimized drug candidates leveraging structural, computational, and drug disposition approaches.

Before joining Fable, Vanita spent over a decade at EMD Serono in progressively responsible roles, contributing to numerous discovery projects, including a named inventorship on Bavencio™, an early success in immune checkpoint inhibition. As Senior Director, Head of Drug Disposition & Design she guided a 100 person, 4 country, international & multi-disciplinary team supporting EMD Serono’s preclinical portfolio and providing DMPK support to clinical programs. In this role she also served on preclinical governance committees for projects spanning oncology, immuno-oncology, auto-immunity, and inflammation. Her expertise covers various modalities, from antibodies to small molecules and degraders, with direct contributions to numerous monoclonal, bispecific, bifunctional and ADC candidates that have advanced to clinical trials. 

Throughout her tenure, Vanita collaborated with visionary leaders to introduce cutting-edge advancements in structural biology, biophysics, and deep learning, paving the way for her current role.Vanita has served the community as a board member for The Protein Society, often speaks on expert panels discussing the role of data science in drug discovery, and devotes time to mentoring aspiring drug hunters.

Vanita earned her bachelor's degree (1st class honours) in Biochemistry from McGill University and holds a PhD in Molecular and Medical Genetics from the University of Toronto. She conducted her post-doctoral training in computational and experimental protein design at the University of Washington in Nobel laureate David Baker's lab.

Zack is our Chief Financial Officer, bringing over 15 years of extensive experience in financial leadership within the biotech sector. His journey includes notable roles as Chief Financial Officer at Ventus Therapeutics and Inception Sciences Canada, where he played integral roles in shaping financial strategies for success.

Prior to his current position, Zack held key financial leadership positions at Versant Ventures and Biotie Therapies, where his expertise in financial management and strategic planning made significant impacts. He also gained valuable insights during his tenure at Johnson & Johnson, contributing to his comprehensive understanding of the industry landscape.

Zack's expertise extends to supporting small biotech companies through mergers & acquisitions and international structures, underscoring his commitment to driving growth and maximizing value for organizations. He holds a BS in finance and accounting from Miami University (Ohio) and an MBA from the Wharton School of the University of Pennsylvania.

Christine brings over two decades of extensive experience in pharmaceutical and biotech program development and leadership to Fable. Her expertise spans the entire spectrum of early-stage development, from target identification and lead development to Phase I/II clinical testing. With a scientific focus on neurodegeneration, lysosomal storage disorders, and rare diseases, she has made significant contributions to preclinical small molecule therapeutic programs at Pfizer and lentiviral gene therapy advancements at AVROBIO, Inc.

In her previous roles, Christine held key scientific and project leadership positions, where she was responsible for developing analytical strategies and assays across various programs, including preclinical, manufacturing, translational sciences, and clinical testing. Her accountability and leadership have been instrumental in driving program success.

Christine holds advanced degrees in Project and Program Management from Brandeis University and in Biology from Brown University. She is excited to leverage her commitment to excellence and her expertise in navigating complex scientific landscapes to contribute to the mission of Fable.

Kirsten brings over two decades of experience in the biotechnology industry. Kirsten’s expertise is in providing strategic and operational support to the CEO and Leadership Team to ensure successful business planning and implementation of all Fable initiatives.

She has extensive experience working with start-up companies guiding them from Seed through IPO in addition to acquisitions and reverse mergers. Prior to joining Fable, she worked with the CEOs at AVROBIO, Organogenesis, Generation Health and Alseres Pharmaceuticals on developing business strategy, managing priority projects and overseeing timing of milestone achievements.

Her career in biotechnology was preceded by business management, consulting and marketing advising Fortune 500 companies, including Fidelity, Ford Motor Company, Goldman Sachs, McDonald's, NBC, Raytheon and Toyota.

Dasha spearheads a machine learning platforms team at Fable Therapeutics, blending her pharmaceutical science background with a robust academic journey spanning molecular pharmacology, biochemistry, biophysics, immunology, and computational chemistry. Her doctoral research at the University of Toronto, under Dr. James Wells, elucidated signaling mechanisms via G protein-coupled receptors and delved into mechanistic modeling of drug-target interactions. During her postdoctoral tenure at The Hospital for Sick Children, Toronto, supervised by Dr. Sergio Grinstein, Dasha explored immunology and cell biology, focusing on mechanisms of macropinocytosis.

Driven by a passion for continuous learning, Dasha embarked on self-directed education in machine learning, seamlessly transitioning into industry. Her impactful contributions as an applied scientist and computational scientist at Cyclica Inc, later acquired by Recursion, underscore her expertise in computational small molecule drug discovery and machine learning models predicting small molecule properties and drug-target interactions. At Fable Therapeutics, Dasha assumed the role of a machine learning engineer, leading the antibody design platform team.

Complementing her industry roles, Dasha is dedicated to nurturing future pharmaceutical scientists as an Assistant Professor, Teaching Stream, at the Faculty of Pharmacy, University of Toronto. Her commitment to education is evident in her lectures on molecular pharmacology, receptor theory, and enzymology, shaping the next generation of pharmaceutical scientists.Dasha's scholarly contributions include six first-author articles and a book chapter, reflecting her commitment to advancing pharmaceutical science.

Joe leads the generative AI team at Fable Therapeutics, leveraging nearly two decades of entrepreneurial experience and a passion for interdisciplinary research.

Joe's journey began with the founding of Shanghai Vastview Tech, where he developed ERP solutions tailored for the hospitality industry. Under his leadership, the company's flagship product gained significant traction, capturing over 70% of the market share in Shanghai and its surrounding areas. Expanding his vision internationally, Joe forged a strategic partnership with Logiclink, extending Vastview Tech's operations into the United States.

Driven by a genuine curiosity in biology and artificial intelligence, Joe pursued further studies at the University of Toronto. There, he developed VARITY, a computational model for predicting the pathogenicity of rare human variants. VARITY's recent success in winning the CAGI6 competition's missense category underscores Joe's contributions to genome interpretation.

Joe's academic background includes a bachelor's degree in engineering from Shanghai JiaoTong University, followed by bachelor’s degrees in computational biology, a master's degree in molecular genetics, and a doctorate in computer science from the University of Toronto.